INTRODUCTION {#S1}
============

Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS), characterized by demyelination and axonal damage^[@R1]^. A widely used animal model for MS studies is experimental autoimmune encephalomyelitis (EAE)^[@R2]^. Initiation of EAE involves peripheral priming of myelin-specific autoimmune T helper 1 (Th1) and Th17 cells and their subsequent migration into the CNS, where they become reactivated by antigen-presenting cells (APCs) displaying myelin-derived peptides and engage in inflammatory processes. These pathological events culminate in disseminated CNS inflammation, leading to the destruction of oligodendrocytes and neurons, and the development of disease symptoms characterized by progressive paralysis^[@R3]^. The pathogenesis of EAE and MS also critically involves microglia^[@R4]-[@R6]^, innate immune cells that seed the CNS early during embryonic development and differ in ontogeny from bone marrow (BM)-derived monocytes and macrophages^[@R7],[@R8]^. Microglia sense microbial invasion and tissue damages, and upon activation, they secrete chemokines and proinflammatory cytokines, thereby mediating leukocyte recruitment into the CNS and the induction of inflammation^[@R9],[@R10]^. Activated microglia also function as APCs in the reactivation of T cells within the CNS^[@R9],[@R11]^.

Microbial infections serve as an environmental trigger for the onset and persistence of MS^[@R1],[@R12]^ as well as the induction of EAE^[@R13]-[@R15]^. Consistently, receptors that detect pathogen-associated molecular patterns, such as toll-like receptors (TLRs), have an important role in the regulation of MS and EAE^[@R16]^. In particular, the TLRs expressed on microglia are thought to mediate microglial activation and CNS inflammation^[@R16]-[@R19]^. TLRs respond to both microbial components and endogenous damage-associated molecular patterns released from apoptotic cells or wounded tissues during the course of autoimmune inflammations. Upon stimulation by their ligands, TLRs elicit cascades of signaling events that lead to activation of the IκB kinase (IKK) and MAP kinases (MAPKs) as well as their downstream transcription factors, NF-κB, AP-1, and related DNA-binding proteins^[@R20]^. These transcription factors act cooperatively to induce the expression of a plethora of genes involved in leukocyte migration and inflammation^[@R20]^.

The MyD88-dependent TLR pathway is particularly important for the pathogenesis of EAE^[@R16],[@R17]^. An E3 ubiquitin ligase, c-IAP, is required for the activation of MAPKs, although not IKK, by the MyD88-dependent TLRs^[@R21]^. Upon activation by the TLR signals, c-IAP mediates K48 ubiquitination and degradation of Traf3, an action required for MAPK activation^[@R21],[@R22]^. However, the mechanism mediating this c-IAP-Traf3 axis of TLR signaling is obscure. The Peli (also called Pellino) family of proteins has been implicated in the regulation of TLR and IL-1 receptor (IL-1R) signaling in innate immune cells^[@R23]-[@R25]^. Mammalian cells express three highly homologous Peli members, which complicates the study of their *in vivo* functions due to potential functional redundancies. Our recent study suggests that in innate immune cells and mouse embryonic fibroblasts (MEFs), Peli1 is dispensable for signal transduction by IL-1R and the MyD88-dependent TLRs, although Peli1 has a nonredundant role in mediating NF-κB activation by the TRIF-dependent TLR pathway^[@R26]^. Whether Peli1 is required for MyD88 TLR signaling in specific cell types and how Peli1 regulates TLR signaling *in vivo* in pathological processes remain elusive. In the present study, we discovered a crucial role for Peli1 in regulating microglial activation and EAE pathogenesis. We provide molecular and genetic evidence that Peli1 mediates the c-IAP-Traf3 signaling axis and, thereby, controls TLR-stimulated Traf3 degradation and MAPK activation.

RESULTS {#S2}
=======

*Peli1*-deficient mice are refractory to EAE induction {#S3}
------------------------------------------------------

To study the role of Peli1 in CNS inflammation, we induced EAE in wild-type and *Peli1*-KO mice using a myelin oligodendrocyte glycoprotein (MOG) peptide (MOG~35--55~). As expected, wild-type mice developed severe clinical symptoms that were characterized by a gradual increase in the severity of paralysis (**[Fig.1a](#F1){ref-type="fig"}**), inflammatory cell infiltration into the CNS (**[Fig. 1b](#F1){ref-type="fig"}**, left), and demyelination (**[Fig. 1b](#F1){ref-type="fig"}**, right). Despite the competent responses of the *Peli1*-KO T cells to antigen stimulation (**[Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}**), these mutant mice were highly resistant to EAE induction (**[Fig. 1a,b](#F1){ref-type="fig"}**). This phenotype of the *Peli1*-KO mice was associated with reduced frequency and number of CNS-infiltrating T cells (CD4^+^ and CD8^+^), myeloid cells and activated resident microglial cells (CD11b^+^CD45^hi^), and total lymphocytes (CD11b^--^CD45^hi^), with concomitant increase in resting microglial cells (CD11b^+^CD45^lo^) (**[Fig. 1c,d](#F1){ref-type="fig"}**).

The CNS of *Peli1*-KO mice also had a greatly reduced number of Th1 and Th17 cells, coupled with their accumulation in the draining lymph nodes (LNs) (**[Fig. 1e](#F1){ref-type="fig"}**). Notably, the CNS of EAE-induced *Peli1*-KO mice had defective expression of various chemokines and inflammatory cytokines known to mediate immune cell recruitment and inflammation (**[Fig. 1f](#F1){ref-type="fig"}**). These results suggest that the *Peli1*-KO mice may have impaired recruitment of T cells into the CNS.

Peli1 regulates EAE induction in radioresistant cells {#S4}
-----------------------------------------------------

To examine the cellular mechanism by which Peli1 regulates EAE pathogenesis, we performed passive EAE induction by adoptively transferring activated MOG-specific T cells into sublethally irradiated wild-type and *Peli1*-KO recipient mice. Transfer of wild-type T cells to wild-type recipient mice (WT to WT), but not to the *Peli1*-KO recipient mice (WT to KO), led to severe EAE disease, suggesting a CNS-specific role for Peli1 in mediating EAE pathogenesis (**[Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}**). On the other hand, Peli1 was dispensable for the EAE-inducing function of T cells, since the MOG-specific *Peli1*-KO T cells were fully competent in EAE induction in wild-type recipients (**[Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}**).

We next generated radiation BM chimeric mice by reconstituting lethally irradiated wild-type or *Peli1*-KO mice with wild-type BM cells isolated from a GFP-transgenic mouse^[@R27]^. The wild-type GFP-chimeric mice were highly susceptible, while the KO GFP-chimeric mice were refractory, to EAE induction (**[Fig. 2a](#F2){ref-type="fig"}**). A reverse BM transfer experiment revealed that Peli1 was dispensable in BM cells for mediating EAE pathogenesis (**[Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}**). These data further support a CNS-specific function for Peli1 in mediating EAE pathogenesis.

Taking advantage of the GFP-chimeric mice described above, we determined whether Peli1 functions in CNS-resident cells to mediate the recruitment of immune cells into the CNS during EAE induction. On day 5 following EAE induction, the CNS of both the wild-type and *Peli1*-KO chimeras had a low frequency of immune cells (GFP^+^) (**[Fig. 2b,c](#F2){ref-type="fig"}**). Over time, the frequency of the CNS-infiltrating immune cells was substantially increased in the wild-type chimeras, but not in the *Peli1*-KO chimeras (**[Fig. 2b,c](#F2){ref-type="fig"}**). Similarly, the *Peli1*-KO chimeras had a severe defect in recruiting CD4^+^ T cells into the CNS (**[Fig. 2d,e](#F2){ref-type="fig"}**). This was not due to a defect in donor T-cell activation, since the spleen of these mutant chimeras contained a considerably higher number of donor CD4^+^ T cells (**[Fig. 2f](#F2){ref-type="fig"}**). The CNS of *Peli1*-KO chimeric mice had considerably reduced expression of proinflammatory cytokine and chemokine genes (**[Fig. 2g](#F2){ref-type="fig"}**). Thus, Peli1 appears to function within the CNS-resident cells to mediate the induction of genes involved in immune cell recruitment and inflammation.

Peli1 has a microglia-specific role in EAE regulation {#S5}
-----------------------------------------------------

The brain and spinal cord were among the tissues with abundant Peli1 expression (**[Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}**). In particular, Peli1 was the predominant Peli family member expressed in microglia, whereas at least two of the three Peli family members were comparably expressed in astrocytes, oligodendrocyte precursor cells (OPCs), and neurons (**[Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}**) or innate immune cells^[@R28]^. Furthermore, Peli1, but not the other Peli family members, was induced in microglia upon *in vitro* stimulation by LPS (**[Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 4c,d](#SD1){ref-type="supplementary-material"}**) or during *in vivo* EAE induction (**[Fig. 3c](#F3){ref-type="fig"}**). The *Peli1* induction along with EAE was transient (**[Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}**).

To examine whether Peli1 is required for microglial activation during EAE induction, we took the advantage of the GFP-chimeric mice to distinguish between the infiltrating macrophages (CD11b^+^GFP^+^) and CNS-resident microglia (CD11b^+^GFP^--^). We detected microglial activation based on their well-defined induction of CD45 and MHC class II (MHC II)^[@R5]^. Following EAE induction, the wild-type chimeras substantially increased the frequency of activated microglia (CD45^hi^MHC II^+^GFP^--^) and decreased the frequency of resting microglia (CD45^lo^MHC II^--^GFP^--^), whereas the *Peli1*-KO chimeras contained predominantly the resting microglia (**[Fig. 3d,e](#F3){ref-type="fig"}**). Purified *Peli1*-deficient microglia were also defective in LPS-stimulated MHC II expression *in vitro* (**[Fig. 3f](#F3){ref-type="fig"}**). The *Peli1*-deficient microglia, isolated from EAE-induced mice, also had impaired expression of proinflammatory cytokine and chemokine genes (**[Fig. 3g](#F3){ref-type="fig"}**). These results suggest the requirement of Peli1 for EAE-associated microglial activation.

As a more direct approach to examine the microglia-specific function of Peli1 in mediating EAE pathogenesis, we stereotaxically injected purified microglia (**[Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}**) into the cerebrospinal fluid of *Peli1*-KO mice. Injection with the wild-type microglia, but not with the *Peli1*-KO microglia, rendered the *Peli1*-KO mice highly sensitive to EAE induction (**[Fig. 3h](#F3){ref-type="fig"}**). These data further emphasize a microglia-specific role for Peli1 in mediating CNS inflammation and EAE induction.

Peli1 mediates TLR-stimulated gene expression in microglia {#S6}
----------------------------------------------------------

Although microglia did not appreciably respond to the TLR3 ligand, poly(I:C), they responded to several ligands of MyD88-dependent TLRs, including LPS (TLR4), CpG (TLR9), R837 (TLR7), and Pam~3~CSK~4~ (TLR1/2), leading to induction of several proinflammatory cytokine and chemokine genes (**[Fig. 4a,b](#F4){ref-type="fig"}**). The Peli1 deficiency severely attenuated the gene induction by these MyD88-dependent TLR ligands (**[Fig. 4a,b](#F4){ref-type="fig"}, [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}**).

EAE pathogenesis also involves the CNS-resident astrocytes, which respond to proinflammatory cytokines, such as IL-17, IFN-γ, and TNF-α. However, the Peli1 deficiency did not appreciably affect such responses in astrocytes (**[Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}**). This result suggests a dispensable role for Peli1 in IL-17R signaling or functional redundancy of Peli1 with other Peli family members that are also expressed in astrocytes (**[Fig. 3a](#F3){ref-type="fig"}**).

Peli1 mediates TLR-stimulated MAPK activation in microglia {#S7}
----------------------------------------------------------

We have previously shown that in MEFs, Peli1 mediates NF-κB activation by the TRIF-dependent TLR pathway, but is dispensable for the MyD88-dependent TLR pathway^[@R26]^. Similarly, we found that the loss of Peli1 in microglia impaired the activation of NF-κB stimulated by the TLR3 ligand poly(I:C) (**[Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}**). In contrast, Peli1 was dispensable for NF-κB activation by the MyD88-dependent TLR ligand Pam~3~CSK~4~ (**[Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}**). The LPS-induced NF-κB activation in *Peli1*-deficient microglia was partially defective (**[Supplementary Fig. 7c](#SD1){ref-type="supplementary-material"}**), reflecting the fact that LPS stimulates both TRIF- and MyD88-dependent pathways^[@R20]^. These results further emphasize that Peli1 regulates NF-κB activation specifically in the TRIF-dependent TLR pathway.

The requirement of Peli1 in gene induction by MyD88-dependent TLRs in microglia (**[Fig. 4a,b](#F4){ref-type="fig"}**) suggested a novel signaling function of Peli1. Indeed, the Peli1 deficiency severely attenuated the LPS-stimulated activation of three major families of MAPKs: ERK, JNK, and p38 (**[Fig. 4c](#F4){ref-type="fig"}**). This function of Peli1 appeared to involve the MyD88-dependent pathway, since Peli1 was also required for MAPK activation by Pam~3~CSK~4~ (**[Fig. 4d](#F4){ref-type="fig"}**).

Peli1 mediates TLR-stimulated c-IAP ubiquitination and TRAF3 degradation {#S8}
------------------------------------------------------------------------

Upon LPS stimulation, activated Traf6 undergoes autoubiquitination^[@R23],[@R24]^ and mediates MAPK activation by inducing K63 ubiquitination of c-IAP, a modification that triggers the ubiquitin ligase activity of c-IAP^[@R21],[@R22]^. We found that the Peli1 deficiency did not inhibit Traf6 ubiquitination but severely attenuated c-IAP2 ubiquitination in LPS-stimulated microglia (**[Fig. 5a](#F5){ref-type="fig"}**). Since Traf6 is required for Peli1 activation^[@R29]^, we surmised that Peli1 might mediate Traf6-induced c-IAP2 ubiquitination. We found that although both Traf6 and Peli1 induced K63 ubiquitination of c-IAP2, the wild-type Peli1 markedly promoted the Traf6-mediated c-IAP2 ubiquitination **([Fig. 5b](#F5){ref-type="fig"}, [Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}**). Conversely, the Traf6-induced c-IAP2 ubiquitination was blocked by expression of the Peli1 RING-deletion mutant (Peli1ΔC) (**[Fig. 5b](#F5){ref-type="fig"}**) and by knocking down endogenous Peli1 by shRNA (**[Fig. 6c](#F6){ref-type="fig"}**). Moreover, the LPS-stimulated K63 ubiquitination of c-IAP2 was attenuated in the *Peli1*-deficient microglia (**[Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}**). These results suggest that Peli1 is essential for the induction of c-IAP ubiquitination by LPS and Traf6.

An important function of c-IAP in the TLR pathway is to mediate K48 ubiquitination and degradation of Traf3, thereby triggering MAPK activation^[@R21],[@R22]^. We found that LPS stimulated rapid degradation of Traf3 in wild-type microglia (**[Fig. 5d](#F5){ref-type="fig"}**), although such a signaling event was much less prominent in BM-derived macrophages (data not shown). The LPS-stimulated Traf3 degradation was blocked in the *Peli1*-deficient microglia (**[Fig. 5d](#F5){ref-type="fig"}**), which could be rescued by reconstitution with exogenous Peli1 (**[Supplementary Fig. 9a](#SD1){ref-type="supplementary-material"}**). Consistently, LPS stimulated Traf3 K48-ubiquitination in wild-type microglia, which was diminished in the *Peli1*-deficient microglia (**[Fig. 5e](#F5){ref-type="fig"}**). A parallel experiment revealed that the TLR2 ligand Pam~3~CSK~4~ also induced Traf3 degradation in wild-type, but not *Peli1*-deficient, microglia (**[Supplementary Fig. 9b](#SD1){ref-type="supplementary-material"}**). Of note, Traf3 was gradually depleted in the microglia of wild-type mice but was accumulated in the microglia of *Peli1*-KO mice along with EAE induction (**[Fig. 5f](#F5){ref-type="fig"}**). Thus, Peli1 mediates the ubiquitin-dependent Traf3 degradation both *in vitro* upon TLR stimulation and *in vivo* along with EAE induction.

Consistent with a recent report that IKKi (also known as IKKε) activates Peli1^[@R30]^, we found that overexpressed Peli1 induced Traf3 ubiquitination, which was promoted by IKKi (**[Fig. 5g](#F5){ref-type="fig"}**). Because c-IAP is known as an E3 of Traf3^[@R21]^, we asked whether Peli1-induced Traf3 ubiquitination required c-IAP. We found that the Peli1-induced Traf3 ubiquitination was blocked in cells treated with the c-IAP inhibitor Smac mimetic^[@R31]-[@R33]^ (**[Fig. 5h](#F5){ref-type="fig"}**) or transfected with the c-IAP1,2 shRNAs (**[Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}**). Collectively, these results suggest that Peli1 activates c-IAP and participates in c-IAP-mediated Traf3 ubiquitination and degradation.

Traf3 ablation restores microglial activation and EAE sensitivity in *Peli1*-KO mice {#S9}
------------------------------------------------------------------------------------

To assess the functional significance of Traf3 degradation in mediating microglial activation, we knocked down Traf3 in *Peli1*-deficient microglia. Infection of the *Peli1*-KO microglia with a Traf3-specific shRNA, but not a control shRNA vector, largely rescued their defect in LPS-stimulated gene induction (**[Fig. 6a](#F6){ref-type="fig"}**). Consistent with this *in vitro* finding, the Traf3^fl/fl^LysM-Cre mice, which had specific Traf3 ablation in microglia and other myeloid-lineage cells, were evidently more sensitive to EAE induction than the control Traf3^+/+^LysM-Cre mice (**[Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"}**). This phenotype was not due to elevation in the production of Th1 or Th17 cells (**[Supplementary Fig. 11b](#SD1){ref-type="supplementary-material"}**) or in the recall responses of MOG-specific T cells (**[Supplementary Fig. 11c](#SD1){ref-type="supplementary-material"}**). On the other hand, the microglia derived from the Traf3^fl/fl^LysM-Cre mice were hyper-responsive to LPS-stimulated expression of proinflammatory cytokine and chemokine genes (**[Supplementary Fig. 11d](#SD1){ref-type="supplementary-material"}**).

The myeloid ablation of Traf3 also rescued the defect of the *Peli1*-KO mice in EAE induction (**[Fig. 6b](#F6){ref-type="fig"}**) and in CNS-infiltration of T cells and CD45^+^CD11b^+^ myeloid cells (**[Fig. 6c,d](#F6){ref-type="fig"}**). Moreover, the Traf3 ablation rescued the defect of the *Peli1*-KO mice in microglial activation, as evidenced by the lack of the accumulation of resting microglial population (CD45^lo^CD11b^+^) (**[Fig. 6c](#F6){ref-type="fig"}**). Taken together, these *in vitro* and *in vivo* studies highlight the functional significance of Peli1-mediated Traf3 degradation in mediating microglial activation and CNS inflammation.

DISCUSSION {#S10}
==========

Microglial activation is an early event in the development of CNS inflammatory disorders, and ablation or functional inhibition of microglia ameliorates EAE induction without affecting peripheral T-cell activation, emphasizing the promise of targeting microglial activation in the treatment of MS^[@R4],[@R34]^. In the present study, we identified the E3 ubiquitin ligase Peli1 as a pivotal mediator of microglial activation and EAE pathogenesis. We have previously shown that peripheral innate immune cells and MEFs express different Peli family members at comparable levels^[@R28]^, which suggests functional redundancies in some of their functions and explains why loss of Peli1 in peripheral innate immune cells selectively affects the TRIF-dependent TLR signaling in the NF-κB pathway^[@R26]^. Our present study revealed that microglia predominantly expressed Peli1 and required Peli1 for their activation during the course of EAE induction and TLR stimulation. In addition to attenuated TRIF-dependent NF-κB activation, the *Peli1*-deficient microglia had impaired activation of MAPKs stimulated by MyD88-dependent TLRs. Like microglia, T cells predominantly express Peli1; however, Peli1 is not required, but it rather serves as a negative regulator for T-cell activation^[@R28]^. In contrast to microglia, several other CNS cell types, including astrocytes, OPCs, and neurons, express different Peli family members at comparable levels. Although the role of Peli1 in mediating TLR signaling in these cell types needs to be further studied, the pattern of Peli expression predicts functional redundancy.

Microglia form a major population of CNS APCs that become activated along with EAE induction^[@R10]^. We found that Peli1 is crucial for mediating microglial activation both *in vivo* along with EAE induction and *in vivo* by LPS stimulation. These findings suggest the requirement of Peli1 in T-cell activation within the CNS. Peli1 is also required for the induction of proinflammatory cytokines and chemokines in microglia, which explains why the Peli1 deficiency impairs immune cell infiltration into the CNS and ameliorated EAE pathogenesis.

A major signaling function of Peli1 in microglia was to mediate the activation of MAPKs by MyD88-dependent TLRs. Peli1 deficiency did not interfere with the TLR-mediated activation of Traf6 but rather appeared to prevent Traf6 from mediating the K63 ubiquitination of c-IAP. Our data are in line with the recent report that Peli1 is a downstream target of Traf6 in the MyD88 TLR pathway^[@R29]^. The K63 ubiquitination of c-IAP is known to trigger its K48 ubiquitin ligase activity, allowing c-IAP to engage ubiquitin-dependent degradation of Traf3^[@R21],[@R22]^. Consistently, Peli1 was required for Traf3 degradation in microglia both *in vitro* upon TLR stimulation and *in vivo* along with EAE induction. By different approaches, we demonstrated that the Traf3 accumulation in *Peli1*-deficient microglia contributes to the impaired inflammatory responses and ameliorated EAE in the *Peli1*-KO mice. Our data are in agreement with a previous report that Traf3 suppresses IL-17-stimulated signaling and EAE pathogenesis in radioresistant cells, likely the CNS cells^[@R35]^. Since IL-17 does not induce Traf3 degradation^[@R35]^, it is likely that the Peli1 may not be directly involved in IL-17R signaling and that the Peli1-mediated Traf3 degradation in the TLR pathway may indirectly promote the IL-17R signaling.

It is currently unclear whether Peli1 is involved in human MS pathogenesis. Nevertheless, a recently published microarray data set suggests elevated Peli1 expression in the initial white matter lesion areas of MS brains^[@R36]^ (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32915>). We also performed microarray studies to analyze gene expression in the grey matters of several MS and non-MS brains. While Peli1 expression was largely comparable between the MS and non-MS samples, one MS sample showed a markedly higher level of Peli1 expression (**[Supplementary Fig. 12 and Supplementary Table 1](#SD1){ref-type="supplementary-material"}**). One technical issue was that the brain tissues contain only a small percentage of microglial cells. Nevertheless, these human study data generally suggest that the expression of Peli1 is altered in MS.

In summary, our work establishes Peli1 as a novel mediator of microglial activation and EAE pathogenesis. Based on our data, we propose a model that Peli1 functions downstream of Traf6 in the MyD88 TLR pathway to mediate the activation of c-IAP and induction of ubiquitin-dependent degradation of Traf3, thereby contributing to the activation of MAPKs and the induction of genes involved in microglial activation and CNS inflammation.

METHODS {#S11}
=======

Methods and any associated references are available in the online version of the paper.
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![*Peli1*-KO mice are resistant to EAE induction\
(**a**) Mean clinical scores of age- and sex-matched wild-type (WT) and *Peli1*-KO mice subjected for MOG~35-55~-induced EAE (n=5/group). (**b**) H&E and Luxol Fast Blue (LFB) staining of spinal cord sections from MOG~35-55~-immunized wild-type and *Peli1*-KO EAE mice for visualizing immune cell infiltration and demyelinization, respectively (arrows). Scale bar, 100 μm. (**c,d**) Flow cytometry analysis of immune cell infiltration into the CNS (brain and spinal cord) of MOG~35-55~-immunized wild-type and *Peli1*-KO mice (n = 5, day 15 post-immunization). Data are presented as a representative plot (**c**) and summary graph (**d**). (**e**) Absolute number of Th1 and Th17 cells in the CNS (brain and spinal cord) and draining LNs of MOG~35-55~-immunized wild-type and *Peli1*-KO mice quantified by flow cytometry (n = 4, day 15 post-immunization). Data are presented as summary graphs. (**f**) QPCR analysis to determine the relative mRNA expression level of genes encoding chemokines (left panel) and proinflammatory cytokines (right panel) in spinal cords of MOG~35-55~-immunized wild-type and *Peli1*-KO mice (n = 4, day 15 post-immunization). Data were normalized to a reference gene, *β-actin*. \*P\<0.05 and \*\*P\<0.01.](nihms-440352-f0001){#F1}

![Peli1 deficiency in radioresistant cells inhibits immune cell recruitment into the CNS and ameliorates EAE pathogenesis\
(**a**) EAE induction of wild-type and *Peli1*-KO mice adoptively transferred with GFP^+^ wild-type BM cells. (**b--e**) Flow cytometry analysis of total CNS-infiltrating cells (GFP^+^, **b,c**) and CNS-infiltrating CD4 T cells (GFP^+^CD4^+^, **d,e**) of the MOG~35-55~-immunized wild-type and *Peli1*-KO GFP-chimeric mice described in **a**, showing a representative plot (**b,d**) and a summary graph (**c,e**). (**f**) Flow cytometry analysis of GFP^+^CD4^+^ cell number in the spleen of MOG~35-55~-immunized wild-type and *Peli1*-KO GFP-chimeric mice. (**g**) QPCR analysis of the indicated genes. \*P\<0.05 and \*\*P\<0.01.](nihms-440352-f0002){#F2}

![Peli1-mediated microglial activation contributes to EAE pathogenesis\
(**a,b**) QPCR analysis of relative mRNA expression for *Peli* family members in non-treated primary microglia (MG), astrocytes (AC), oligodendrocyte precursor cells (OPC), and neurons (**a**) or in non-treated (NT) and LPS-stimulated microglia (**b**). (**c**) QPCR analysis of *Peli* family member expression in FACS-sorted GPF^--^CD11b^+^ microglia isolated from the non-immunized or EAE-induced (15 day after MOG~35-55~ immunization) GFP-chimeric mice described in **[Fig. 2a](#F2){ref-type="fig"}**. (**d**) Flow cytometry analysis of activation markers (CD45 and MHC class II) on gated GFP^−^CD11b^+^ microglia isolated from the CNS of wild-type or *Peli1*-KO GFP-chimeric mice, which were either non-immunized or immunized for the indicated days of EAE induction. Data are representative of 4 animals per group and time points. (**e**) Summary graph of **d**, showing the mean ± S.D. of the frequency value of resting (GFP^−^CD11b^+^CD45^lo^MHC II^−^) and activated (GFP^−^CD11b^+^CD45^hi^MHC II^+^) microglia at the two indicated time points. (**f**) Flow cytometry analysis of MHC II expression on wild-type and *Peli1*-KO primary microglia that were either not treated (NT) or stimulated with LPS *in vitro* for the indicated times. (**g**) QPCR analysis of the indicated genes in FACS-sorted GPF^--^CD11b^+^ microglia isolated from EAE-induced (day 15 post-immunization) wild-type or *Peli1*-KO GFP-chimeric mice. (**h**) EAE induction in wild-type or *Peli1*-KO mice that were stereotaxically injected, on day 3 of MOG~35-55~ immunization, with PBS, *Peli1*-KO microglia (KO MG), or wild-type microglia (WT MG). Mean clinical scores were determined based on 5 mice per group. \*P\<0.05 and \*\*P\<0.01.](nihms-440352-f0003){#F3}

![Peli1 mediates TLR-stimulated gene expression and MAPK activation in microglia\
(**a,b**) QPCR analysis of relative mRNA expression for the indicated proinflammatory cytokine genes (**a**) and chemokine genes (**b**) in wild-type and *Peli1*-KO microglia stimulated with ligands of different TLRs: TLR4 (LPS, 100 ng ml^--^), TLR9 (CpG, 2.5 μM^--^), TLR7/8 (R837, 1 μg ml^--^), TLR1/2 (Pam~3~CSK~4~, 1 μg ml^--^), and TLR3 (poly(I:C), 10 μg ml^--^). (**c,d**) IB analysis of phosphorylated (P-) and total MAPKs in whole-cell lysates of wild-type or *Peli1*-KO microglia stimulated with LPS (100 ng ml^--^) (**c**) or Pam~3~CSK~4~ (1 μg ml^--^) (**d**). The protein bands were quantified using ImageJ and presented as fold of phosphorylated over total MAPKs. Data are mean±S.D. values based on three independent experiments. \*P\<0.05 and \*\*P\<0.01.](nihms-440352-f0004){#F4}

![Peli1 regulates TLR-stimulated c-IAP2 ubiquitination and Traf3 degradation\
(**a**) Ubiquitination of Traf6 (upper) and c-IAP2 (lower) in LPS-stimulated wild-type or *Peli1*-KO microglia. (**b**) Ubiquitination of c-IAP2 (upper) and expression of the indicated proteins (lower) in HEK293 cells transfected with (+) or without (--) the indicated expression vectors. (**c**) Ubiquitination of c-IAP2 (upper) and expression of the indicated proteins (lower) in HEK293 cells transfected with (+) or without (--) the indicated cDNA expression vectors or Peli1 shRNA. (**d**) IB analysis of Traf3 and actin in whole-cell lysates of LPS-stimulated wild-type and *Peli1*-KO microglia. (**e**) Analysis of Traf3 K48 ubiquitination in wild-type or Peli1 KO microglia stimulated with LPS in the presence of a proteasome inhibitor, MG132. (**f**) IB analysis of Traf3 and actin in whole-cell lysates of FACS-sorted GPF^--^CD11b^+^ microglia isolated from non-immunized (0 d) or EAE-induced (7 and 14 d) GFP-chimeric mice (as described in **[Fig. 2a](#F2){ref-type="fig"}**). NS indicates a nonspecific band. (**g**) Ubiquitination of Traf3 (upper) and expression of the indicated proteins (lower) in HEK293 cells transfected with the indicated expression vectors. (**h**) Ubiquitination of Traf3 (upper) and expression of the indicated proteins (lower) in HEK293 cells transfected with (+) or without (--) the indicated expression vectors and subsequently (after 10 h of transfection) cultured in the absence (--) or presence (+) of Smac mimetic (SM, 1 μM) for another 24 h.](nihms-440352-f0005){#F5}

![Traf3 ablation restores proinflammatory gene induction in *Peli1*-deficient microglia and EAE induction in *Peli1*-deficient mice\
(**a**) QPCR analysis of the indicated mRNAs in nontreated (NT) or LPS-stimulated wild-type and *Peli1*-KO microglia infected with control vector or Traf3 shRNA. \*P\<0.05. (**b**) Mean clinical scores of *the indicated* mice subjected for MOG~35-55~-induced EAE (n=5/group). (**c,d**) Flow cytometry analysis of immune cell infiltration into the CNS (brain and spinal cord) of the indicated mice at 30 days following MOG~35-55~-mediated EAE induction (n = 4). Data are presented as a representative plot (**c**) and summary graph (**d**).](nihms-440352-f0006){#F6}
